<DOC>
	<DOCNO>NCT00005970</DOCNO>
	<brief_summary>This randomized phase III trial study doxorubicin hydrochloride , cyclophosphamide , paclitaxel , trastuzumab see well work compare combination chemotherapy alone treat woman breast cancer human epidermal growth factor receptor 2 ( HER2 ) -positive spread lymph node high-risk spread lymph node . Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Monoclonal antibody trastuzumab locate tumor cell either kill deliver tumor-killing substance without harm normal cell . It yet know whether combination chemotherapy effective without trastuzumab treat breast cancer .</brief_summary>
	<brief_title>Doxorubicin Hydrochloride , Cyclophosphamide , Pacltaxel With Without Trastuzumab Treating Women With HER2-Positive Node-Positive High-Risk Node-Negative Breast Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To compare combination doxorubicin hydrochloride cyclophosphamide ( AC ) follow weekly paclitaxel combination AC follow combination weekly paclitaxel trastuzumab term disease free survival ( DFS ) . ( Stage I ) II . To compare combination AC follow weekly paclitaxel combination AC follow combination weekly paclitaxel trastuzumab term rate cardiac event . ( Stage I ) III . To compare combination AC follow weekly paclitaxel sequential schedule combination AC , weekly paclitaxel , trastuzumab term DFS . ( Stage II ) IV . To compare sequential schedule combination AC , weekly paclitaxel , trastuzumab combination AC follow combination weekly paclitaxel trastuzumab term DFS . ( Stage II ) V. To compare combination AC follow weekly paclitaxel sequential schedule combination AC , weekly paclitaxel , trastuzumab term rate cardiac event . ( Stage II ) SECONDARY OBJECTIVES : I . To compare combination AC follow weekly paclitaxel sequential schedule combination AC , weekly paclitaxel , trastuzumab term overall survival ( OS ) . II . To compare combination AC follow weekly paclitaxel combination AC follow combination weekly paclitaxel trastuzumab term OS . III . To compare sequential schedule combination AC , weekly paclitaxel , trastuzumab combination AC follow combination weekly paclitaxel trastuzumab term OS . TERTIARY OBJECTIVES : I . To determine whether high level shed ECD ( extracellular domain ) autoantibodies human epidermal growth factor receptor ( HER ) -2 HER-1 measure serum prior treatment prognostic DFS survival . II . To determine concordance central review HER-2 overexpression measure HercepTest ( DAKO ) Vysis fluorescence situ hybridization ( FISH ) . III . For treatment arm , level brain natriuretic peptide ( BNP ) , troponin-T ( TnT ) , troponin-I ( cTnI ) , tumor necrosis factor alpha ( TNF-alpha ) , interleukin-1 beta ( IL-1beta ) interleukin-6 ( IL-6 ) , CD40 ligand , troponin level compare contrast . IV . To determine whether genetic marker prognostic cardiac adverse event associate treatment . OUTLINE : Patients randomize 1 3 treatment arm . ARM I* : Patients receive doxorubicin hydrochloride intravenously ( IV ) cyclophosphamide IV 20-30 minute day 1 . Treatment repeat every 3 week 4 course . Patients receive paclitaxel IV 1 hour begin day 1 week 13 continue weekly 12 course absence disease progression unacceptable toxicity . NOTE : *Patients complete paclitaxel October 25 , 2004 may receive trastuzumab maximum 52 week either concurrently paclitaxel follow completion paclitaxel treatment . ARM II* : Patients receive doxorubicin hydrochloride , cyclophosphamide , paclitaxel arm I . Patients receive trastuzumab IV 30-90 minute begin day 1 week 25 continue weekly 52 course absence disease progression unacceptable toxicity . NOTE : *Patients complete paclitaxel October 25 , 2004 may receive trastuzumab maximum 52 week either concurrently paclitaxel follow completion paclitaxel treatment . ARM III : Patients receive doxorubicin hydrochloride cyclophosphamide arm I . Patients receive paclitaxel IV 1 hour trastuzumab IV 30-90 minute begin day 1 week 13 continue weekly 12 course . Patients receive trastuzumab IV 30 minute begin day 1 week 25 continue weekly 40 course absence disease progression unacceptable toxicity . Within 5 week completion paclitaxel , patient may undergo radiotherapy . All postmenopausal estrogen receptor ( ER ) - progesterone receptor ( PR ) -positive patient receive oral tamoxifen aromatase inhibitor daily 5 year begin later 5 week last dose paclitaxel . Patients may also receive aromatase inhibitor daily 5 year 5 year daily tamoxifen . Patients receive tamoxifen daily less 4.5 year may receive aromatase inhibitor daily receive total 5 year adjuvant hormonal therapy . After completion study treatment , patient follow every 3 month 1 year , every 6 month 4 year , annually 15 year disease progression .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Aromatase Inhibitors</mesh_term>
	<criteria>Required tumor parameter node positive disease : NOTE : This study continue use American Joint Committee Cancer ( AJCC ) 5th edition TNM classification stag Operable , histologically confirm adenocarcinoma female breast positive lymph node Node positivity may determine either axillary node dissection positive sentinel node find hematoxylin eosin ( H &amp; E ) NOTE : Positive node refers H &amp; E visible nodal metastasis ; immunohistochemistry ( IHC ) positive cell lymph node consider positive node One positive lymph node whose tumor T13 , pN12 , M0 eligible cN2 disease eligible pN2 disease eligible One positive lymph node sentinel node biopsy least 6 axillary node must examine axillary node dissection least one positive lymph node Metaplastic carcinoma eligible ER/PgR determination HER2 positive ( preentry requirement registration ) FISH must show gene amplification OR IHC assay must show strong positive ( 3+ ) stain score NOTE : ductal carcinoma situ ( DCIS ) component count determination degree IHC stain FISH amplification Required tumor parameter highrisk nodenegative disease ; NOTE : This study continue use AJCC 5th edition TNM classification stag Operable , histologically confirm adenocarcinoma female breast negative lymph node Node status may determine either axillary node dissection sentinel node biopsy H &amp; E staining ; consider node negative , either follow must true : 1 ) negative sentinel node biopsy 2 ) positive lymph node find among least 6 axillary node examine axillary node dissection NOTE : IHC positive cell lymph node consider positive node Tumors &gt; 2.0 cm ( irrespective hormonal receptor status ) &gt; 1.0 cm ERnegative PRnegative disease ER/PgR determination HER2 positive ( preentry requirement registration ) FISH must show gene amplification OR IHC assay must show strong positive ( 3+ ) stain score NOTE : DCIS component count determination degree IHC stain FISH amplification = &lt; 84 day mastectomy = &lt; 84 day axillary dissection sentinel node detection patient 's extensive breast surgery breast sparing procedure ; ( This timing per decision Breast Intergroup ) Surgical resection margin . All tumor remove either modified radical mastectomy segmental mastectomy axillary node dissection Mastectomy : There evidence gross microscopic tumor ( invasive DCIS ) surgical resection margin note final surgery pathology report ; patient close margin eligible Segmental mastectomy ( lumpectomy ) : Margins must clear invasive cancer DCIS Axillary dissection sentinel node dissection : There gross residual adenopathy TAM therapy May receive four week TAM therapy , hormonal agent , malignancy May receive TAM raloxifene purpose chemoprevention ( e.g. , Breast Cancer Prevention Trial ) indication ( include previous breast cancer lobular carcinoma situ [ LCIS ] ) must discontinue registration study May never receive TAM , raloxifene , hormonal agent Absolute neutrophil count ( ANC ) &gt; = 1500/mm^3 Platelets ( PLT ) &gt; = 100,000/mm^3 Total bilirubin = &lt; 1.5 x upper normal limit ( UNL ) Aspartate aminotransferase ( AST ) = &lt; 2.0 x UNL Left ventricular ejection fraction ( LVEF ) within institutional normal range ; LVEF &gt; 75 % , investigator consider perform second review multigated acquisition ( MUGA ) /echocardiogram perform repeat MUGA/echocardiogram prior registration ; rereviews repeat MUGA/echocardiogram permit registration Willingness discontinue sex hormonal therapy , e.g. , birth control pill , ovarian hormonal replacement therapy , etc. , prior registration study Willingness discontinue hormonal agent raloxifene ( Evista ) prior registration study Nonbreast malignancy recur within last 5 year deem low risk recurrence EXCEPTIONS : These nonbreast malignancy eligible even diagnose = &lt; 5 year prior registration : Squamous basal cell carcinoma skin effectively treat Carcinoma situ cervix treat surgery Lobular carcinoma situ ( LCIS ) ipsilateral contralateral breast treat surgery and/or tamoxifen Patients undergoing breast conservation therapy ( i.e. , lumpectomy axillary dissection ) must plan receive radiation therapy breast +/ regional lymphatics follow completion chemotherapy ; patient treat mastectomy , use radiation therapy require 4 positive lymph node must start completion chemotherapy ; use radiation therapy discretion investigator 03 positive lymph node , use , must start completion chemotherapy Prior registration , physician must designate plan patient receive radiation therapy ( adjuvant radiation therapy postmastectomy , less commonly , postconservative therapy primary breast radiation part breast conserve treatment ) Willing able sign inform consent Gene amplify FISH strong positivity ( 3+ ) HercepTest central review ; Note : The patient register base community HER2 test use FISH IHC , AC chemotherapy initiate ; tumor block slide must receive = &lt; 2 week time registration North Central Cancer Treatment Group ( NCCTG ) Operations Office central HER2 test Any following : Pregnant woman Nursing woman Women childbearing potential sexual partner unwilling employ adequate contraception ( condom , diaphragm , intrauterine device [ IUD ] , surgical sterilization , abstinence , etc . ) ; hormonal birth control method permit Locally advance tumor ( classification T4 ) diagnosis include tumor fix chest wall , peau d'orange , skin ulcerations/nodules , clinical inflammatory change ( diffuse brawny cutaneous induration erysipeloid edge ) Prior history breast cancer , except LCIS Bilateral invasive carcinoma , either metachronous synchronous ( EXCEPTION : Patients diagnose unilateral invasive carcinoma metachronous synchronous DCIS contralateral breast treat mastectomy eligible ) Prior chemotherapy , radiation therapy , immunotherapy , biotherapy breast cancer Active , unresolved infection Active cardiac disease Any prior myocardial infarction History document congestive heart failure ( CHF ) Current use digitalis betablockers CHF Any prior history arrhythmia cardiac valvular disease require medication clinically significant Current use medication treatment arrhythmia angina pectoris Current uncontrolled hypertension ( diastolic &gt; 100 mmHg systolic &gt; 200 mmHg ) Clinically significant pericardial effusion Prior anthracycline taxane therapy malignancy Sensitivity benzyl alcohol Neurology/NeuropathySensory &gt; = grade 2 per National Cancer Institute 's ( NCI 's ) Common Toxicity Criteria Version 2.0 ; EXCEPTION : Any chronic neurologic disorder look casebycase basis study chair</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>